Lung cancer combo trial halted early: what we know
NCT ID NCT04549428
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether adding a single dose of radiation to the immunotherapy drug atezolizumab could help people with advanced lung cancer whose disease had gotten worse after both chemotherapy and another type of immunotherapy. The trial planned to include 12 adults with stage IV non-small cell lung cancer. However, the study was terminated early, so the full results are not available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC STAGE IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cantonal Hospital of Graubünden (KSGR)
Chur, 7000, Switzerland
-
Geneva University Hospitals (HUG)
Geneva, 1205, Switzerland
-
Oncology Institute of Southern Switzerland
Bellinzona, 6500, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New antibody drug targets Cancer-Related fluid in the lungs
- New drug cocktail shows promise for Hard-to-Treat lung cancer
- New hope for drug-resistant lung cancer: combo therapy enters trial
- New scan may reveal who will benefit from immunotherapy
- Can extra immunotherapy stall advanced lung cancer?
- Blood test may predict lung cancer drug success